1. Homepage
  2. Equities
  3. France
  4. Euronext Paris
  5. TME Pharma N.V.
  6. News
  7. Summary
    ALTME   NL0015000YE1

TME PHARMA N.V.

(ALTME)
  Report
Real-time Estimate Tradegate  -  03:16 2022-08-15 am EDT
4.660 EUR   -0.85%
08/03TME Pharma Treats First Brain Cancer Patient In Phase 1/2 Clinical Study
MT
08/03TME Pharma Announces Enrollment of First Patient in Pembrolizumab Expansion Arm of NOX-A12 GLORIA Phase 1/2 Brain Cancer Clinical Trial
CI
07/15NOXXON PHARMA N : Inside Information / Other news releases
PU
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsOther languagesPress ReleasesOfficial PublicationsSector news

NOXXON Pharma N : announces Euro 1.2M equity raise through conversion of warrants by Kreos Capital and other historical investors

04/30/2021 | 11:59am EDT

NOXXON ANNOUNCES €1.2M EQUITY RAISE THROUGH CONVERSION OF WARRANTS BY KREOS CAPITAL AND OTHER HISTORICAL INVESTORS

Berlin, Germany, April 30, 2021, 06.00 p.m. CEST - NOXXON Pharma N.V. (Euronext Growth Paris: ALNOX), a biotechnology company focused on improving cancer treatments by targeting the tumor microenvironment (TME), announced that it has received exercise notices from Kreos Capital along with other historical investors who have converted warrants to shares.

A total of 3,768,449 new shares in NOXXON shall be issued consequently to the transaction, and NOXXON shall receive €1.2 million. This brings the total number of outstanding shares in NOXXON to 65,223,981. Following this warrant exercise, Kreos Capital holds 7.38% of outstanding shares in

NOXXON.

The warrants were issued in connection with NOXXON's €1 million private placement, Kreos Capital's partial conversion of debt into equity and €10 million convertible notes with warrants on May 2, 2017. Details of the transaction can be found in the associated press release.

"We are pleased to exercise these warrants and increase our investment in NOXXON. We have been involved in NOXXON since 2014 and are confident the company has exciting long-term prospects, based on its differentiated technology, strong oncology-focused pipeline and the development strategy being implemented by management," said Aris Constantinides, General Partner at Kreos Capital.

"I would like to thank Kreos Capital for their ongoing long-term support of NOXXON. We look forward to working closely together as we continue to focus on improving cancer treatments by targeting the tumor microenvironment, including our lead candidate NOX-A12, which is progressing well in a Phase 1/2 brain cancer trial, with data read-outs expected in May and November 2021," said Aram Mangasarian, CEO of NOXXON.

For more information, please contact:

NOXXON Pharma N.V. Aram Mangasarian, Ph.D. Chief Executive Officer Tel. +49 (0) 30 726247 0 amangasarian@noxxon.com

Investor Relations

LifeSci Advisors Guillaume van Renterghem Tel. +41 (0) 76 735 01 31 gvanrenterghem@lifesciadvisors.com

NewCap Arthur Rouillé

Tel. +33 (0) 1 44 71 00 15 arouille@newcap.fr

About NOXXON

NOXXON's oncology-focused pipeline acts on the tumor microenvironment (TME) and the cancer immunity cycle by breaking the tumor protection barrier and blocking tumor repair. By neutralizing chemokines in the TME, NOXXON's approach works in combination with other forms of treatment to weaken tumor defenses against the immune system and enable greater therapeutic impact. NOXXON's lead program NOX-A12 has delivered final top-line data from a Keytruda® combination trial in metastatic colorectal and pancreatic cancer patients published at the ESMO conference in September 2020 and based on the trial results, including overall survival and safety profile, further studies are being planned in pancreatic cancer. NOXXON is also studying NOX-A12 in brain cancer in combination with radiotherapy which has been granted orphan drug status in the US and EU for the treatment of certain brain cancers. A trial of NOX-A12 in combination with radiotherapy in newly diagnosed brain cancer patients who will not benefit from standard chemotherapy has delivered preliminary data from the first cohort showing consistent tumor reductions. The company's second clinical-stage asset NOX-E36 is a Phase 2 TME asset targeting the innate immune system. NOXXON plans to test NOX-E36 in patients with solid tumors both as a monotherapy and in combination. Further information can be found at: www.noxxon.com

Keytruda® is a registered trademark of Merck Sharp & Dohme Corp

https://www.linkedin.com/company/noxxon-pharma-ag

https://twitter.com/noxxon_pharma

Disclaimer

Certain statements in this communication contain formulations or terms referring to the future or future developments, as well as negations of such formulations or terms, or similar terminology. These are described as forward-looking statements. In addition, all information in this communication regarding planned or future results of business segments, financial indicators, developments of the financial situation or other financial or statistical data contains such forward-looking statements. The company cautions prospective investors not to rely on such forward-looking statements as certain prognoses of actual future events and developments. The company is neither responsible nor liable for updating such information, which only represents the state of affairs on the day of publication.

Disclaimer

Noxxon Pharma NV published this content on 30 April 2021 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 30 April 2021 15:58:05 UTC.


© Publicnow 2021
All news about TME PHARMA N.V.
08/03TME Pharma Treats First Brain Cancer Patient In Phase 1/2 Clinical Study
MT
08/03TME Pharma Announces Enrollment of First Patient in Pembrolizumab Expansion Arm of NOX-..
CI
07/15NOXXON PHARMA N : Inside Information / Other news releases
PU
07/15French Drugmaker Noxxon Changes Name to TME Pharma
MT
07/15NOXXON PHARMA N.V. : Change of company name
CO
07/13Noxxon pharma announces changes to its supervisory board
AQ
07/13Noxxon pharma - half-yearly report on the liquidity contract with invest securities
AQ
07/12NOXXON Pharma N.V. Announces Resignation of Gregory Weaver from its Supervisory Board, ..
CI
07/12NOXXON PHARMA N.V. : Nomination
CO
07/07NOXXON PHARMA N : Bryan Jennings
PU
More news
Financials
Sales 2022 13,4 M 13,7 M 13,7 M
Net income 2022 - - -
Net Debt 2022 - - -
P/E ratio 2022 -
Yield 2022 -
Capitalization 3,96 M 4,06 M 4,06 M
Capi. / Sales 2022 0,30x
Capi. / Sales 2023 0,06x
Nbr of Employees 13
Free-Float 12,3%
Chart TME PHARMA N.V.
Duration : Period :
TME Pharma N.V. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends TME PHARMA N.V.
Short TermMid-TermLong Term
TrendsNeutralBearishBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 1
Last Close Price 4,70 €
Average target price 83,00 €
Spread / Average Target 1 666%
Managers and Directors
Aram Andrew Mangasarian Chief Business Officer
Bryan Jennings Chief Financial Officer & Statutory Director
Maurizio PetitBon Chairman-Supervisory Board
Cornelis Alexander Izeboud Member-Supervisory Board
Martine J. van Vugt Member-Supervisory Board
Sector and Competitors
1st jan.Capi. (M$)
TME PHARMA N.V.-79.91%4
MODERNA, INC.-32.60%66 966
IQVIA HOLDINGS INC.-12.88%45 846
LONZA GROUP AG-25.13%44 851
SEAGEN INC.10.05%31 380
ALNYLAM PHARMACEUTICALS, INC.37.90%28 068